Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection (MRSA-2)

This study has suspended participant recruitment.
(Enrollment was stopped due to staffing issues.)
Sponsor:
Collaborators:
Infectious Diseases Clinical Research Program
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Brian Agan, Uniformed Services University of the Health Sciences
ClinicalTrials.gov Identifier:
NCT00859677
First received: March 10, 2009
Last updated: June 14, 2016
Last verified: June 2016
  Purpose
The purpose of this study is to investigate the role of T helper 17 cells (Th17) in the pathogenesis of MRSA infections.

Condition
HIV Infections
Staphylococcal Infections

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

Resource links provided by NLM:


Further study details as provided by Uniformed Services University of the Health Sciences:

Primary Outcome Measures:
  • To compare distribution of Th17 cells and their functionality, in the peripheral blood of HIV-positive patients who are infected with MRSA with that of HIV-positive patients who are not colonized or infected with Staphylococcus aureus. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare distribution of Th17 cells in the peripheral blood of groups of HIV-positive and HIV-negative participants who are colonized with MRSA as well as those who have a MRSA infection. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Examine distribution of T cells, B cells, macrophages, dendritic cells, neutrophils, defensins, and IL-17 in T cell subsets in the skin [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Compare Th17 cells in peripheral blood of HIV-negative participants with MRSA infection with that of HIV-negative subjects not colonized of infected with Staph aureus. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Collect information on factors that may play a role in development of MRSA colonization/infection. Includes demographic, hygienic, exercise-related, and sexual factors which may contribute to MRSA. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Skin biopsy will be obtained.

Enrollment: 52
Study Start Date: March 2009
Estimated Study Completion Date: December 2016
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
HIV-positive and MRSA negative
2
HIV-positive and MRSA infected (skin/soft tissue)
3
HIV-positive and MRSA colonized
4
HIV-negative and MRSA negative
5
HIV-negative and MRSA infected (skin/soft tissue)
6
HIV-negative and MRSA colonized

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
HIV-positive and negative patients with a recent screen for MRSA colonization or a history of MRSA infection will be asked to participate. Participants will be recruited by providers within the infectious disease clinics at the sites. In addtion, MRSA isolates will be monitored at the central laboratory and providers of patients with MRSA will be notified and asked to notify their patients of the opportunity to participate in this study.
Criteria

All participant inclusion criteria:

  • Greater or equal to 18 years of age
  • Willingness to undergo blood draw. Skin biopsy will be requested, but is optional

-AND-

HIV-positive and MRSA-negative Group:

  • Documented positive HIV test result
  • Negative colonization swabs for S. aureus within 14 days of enrollment
  • No evidence of skin/soft tissue infection

HIV-positive and MRSA-Colonization Group:

  • Documented positive HIV test result
  • History of of colonization with MRSA w/in 14 days of study enrollment

HIV-positive and MRSA Infection Group:

  • Documented positive HIV test result
  • Skin/soft tissue infection with a positive wound culture showing MRSA within 7 days of enrollment
  • MRSA infection is not associated with an intravenous catheter or other nosocomial procedure

HIV Negative groups:

  • Same criteria used for the HIV-negative groups as listed above.
  • No history of HIV infection.
  • Willing to undergo an HIV blood test, which must have a negative result.

Exclusion Criteria:

  • Women with positive urine pregnancy test within 7 days of study enrollment
  • Women who are within 6 months of being postpartum or who are currently breastfeeding
  • Subjects unable or unwilling to complete questionnaires and blood draw.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00859677

Locations
United States, California
Naval Medical Center San Diego
San Diego, California, United States, 92134
United States, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland, United States, 20889
Sponsors and Collaborators
Uniformed Services University of the Health Sciences
Infectious Diseases Clinical Research Program
National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Publications:
Responsible Party: Brian Agan, Deputy Science Director, IDCRP, Uniformed Services University of the Health Sciences
ClinicalTrials.gov Identifier: NCT00859677     History of Changes
Other Study ID Numbers: IDCRP -023 
Study First Received: March 10, 2009
Last Updated: June 14, 2016
Health Authority: United States: Federal Government

Keywords provided by Uniformed Services University of the Health Sciences:
HIV
Methicillin-resistant Staphylococcus aureus (MRSA)
HIV and Staphylococcus aureus infection

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Staphylococcal Infections
Disease Susceptibility
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Gram-Positive Bacterial Infections
Bacterial Infections
Disease Attributes
Pathologic Processes
Methicillin
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on September 23, 2016